Department of Thoracic Surgery, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China.
Department of Cardiovascular Surgery, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China.
Sci Rep. 2023 Sep 27;13(1):16226. doi: 10.1038/s41598-023-42801-y.
Aberrant levels of the G2/M cyclin cyclin B1 (gene CCNB1) have been associated with multiple cancers; however, the literature lacks a focused and comprehensive analysis of the regulation of this important regulator of cell proliferation in cancer. Through this work, we performed a pancancer analysis of the levels of CCNB1 and dissected aspects of regulation and how this correlates with cancer prognosis. We comprehensively evaluated the expression and promoter methylation of CCNB1 across 38 cancers based on RNA sequencing data obtained from the Cancer Genome Atlas (TCGA). The correlation of CCNB1 with prognosis and the tumor microenvironment was explored. Using lung adenocarcinoma data, we studied the potential upstream noncoding RNAs involved in the regulation of CCNB1 and validated the protein levels and prognostic value of CCNB1 for this disease site. CCNB1 was highly expressed, and promoter methylation was reduced in most cancers. Gene expression of CCNB1 correlated positively with poor prognosis of tumor patients, and these results were confirmed at the protein level using lung adenocarcinoma. CCNB1 expression was associated with the infiltration of T helper cells, and this further correlated with poor prognosis for certain cancers, including renal clear cell carcinoma and lung adenocarcinoma. Subsequently, we identified a specific upstream noncoding RNA contributing to CCNB1 overexpression in lung adenocarcinoma through correlation analysis, expression analysis and survival analysis. This study provides a comprehensive analysis of the expression and methylation status of CCNB1 across several forms of cancer and provides further insight into the mechanistic pathways regulating Cyclin B1 in the tumorigenesis process.
G2/M 期周期蛋白 cyclin B1（基因 CCNB1）的异常水平与多种癌症有关；然而，文献中缺乏对细胞增殖这一重要调节因子在癌症中调控作用的集中和全面分析。通过这项工作，我们对 CCNB1 的水平进行了泛癌症分析，并剖析了其调节的各个方面，以及这与癌症预后的相关性。我们根据癌症基因组图谱（TCGA）获得的 RNA 测序数据，全面评估了 CCNB1 在 38 种癌症中的表达和启动子甲基化情况。我们还探讨了 CCNB1 与预后和肿瘤微环境的相关性。使用肺腺癌数据，我们研究了参与 CCNB1 调控的潜在上游非编码 RNA，并验证了 CCNB1 在该疾病部位的蛋白水平和预后价值。在大多数癌症中，CCNB1 的表达上调，启动子甲基化减少。CCNB1 的基因表达与肿瘤患者的预后不良呈正相关，这些结果在肺腺癌中通过蛋白水平得到了证实。CCNB1 的表达与辅助性 T 细胞的浸润有关，这与某些癌症（包括肾透明细胞癌和肺腺癌）的不良预后进一步相关。随后，我们通过相关性分析、表达分析和生存分析，确定了一种特定的上游非编码 RNA，它有助于肺腺癌中 CCNB1 的过表达。本研究对几种癌症中 CCNB1 的表达和甲基化状态进行了全面分析，并进一步深入了解了调节细胞周期蛋白 B1 在肿瘤发生过程中的机制途径。
